Relation of Genetic Polymorphisms in the Cytochrome P450 Gene With Clopidogrel Resistance After Drug-Eluting Stent Implantation in Koreans

American Journal of Cardiology

Volumn 104, Issue 1, 2009, Pages 46-51

  Lee, Jung Myung ^a   Park, Sungha ^a   Shin, Dong Jik ^a,b   Choi, Donghoon ^a   Shim, Chi Young ^a   Ko, Young Guk ^a   Kim, Jung Sun ^a   Shin, Eun Soon ^c   Chang, Chong Won ^d   Lee, Jong Eun ^c   Jang, Yangsoo ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c DNA Link Inc   (South Korea)

^d Dongguk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 2C19; PURINERGIC P2Y12 RECEPTOR;

ADULT; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DRUG ELUTING STENT; ENZYME ASSAY; FEMALE; FIBRINOLYTIC THERAPY; GENETIC ANALYSIS; GENETIC RISK; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ARYL HYDROCARBON HYDROXYLASES; CONFIDENCE INTERVALS; CORONARY ARTERY DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; KOREA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TETRAZOLES; TICLOPIDINE;

EID: 67649370752     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.02.045     Document Type: Article

References (29)

1. Gurbel P.A., and Tantry U.S. Clopidogrel resistance?. Thromb Res 120 (2007) 311-321
2. Steinhubl S.R., Berger P.B., Mann J.T., Fry E.T., DeLago A., Wilmer C., and Topol E.J. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
3. Gurbel P.A., Bliden K.P., Hayes K.M., Yoho J.A., Herzog W.R., and Tantry U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45 (2005) 1392-1396
4. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Barrera-Ramirez C., Sabate M., Hernandez R., Moreno R., Escaned J., Alfonso F., Banuelos C., Costa M.A., Bass T.A., and Macaya C. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 115 (2005) 101-108
5. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., Novikov I., Pres H., Savion N., Varon D., and Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
6. Mobley J.E., Bresee S.J., Wortham D.C., Craft R.M., Snider C.C., and Carroll R.C. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 93 (2004) 456-458
7. Muller I., Besta F., Schulz C., Massberg S., Schonig A., and Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Res 89 (2003) 783-787
8. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Sabate M., Jimenez-Quevedo P., Hernandez R., Moreno R., Escaned J., Alfonso F., Banuelos C., Costa M.A., Bass T.A., and Macaya C. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54 (2005) 2430-2435
9. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramírez C., Barrera-Ramirez C., Sabaté M., Hernández R., Moreno R., Escaned J., Alfonso F., Bañuelos C., Costa M.A., Bass T.A., and Macaya C. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 115 (2005) 101-108
10. Järemo P., Lindahl T.L., Fransson S.G., and Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 252 (2002) 233-238
11. Müller I., Besta F., Schulz C., Massberg S., Schönig A., and Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89 (2003) 783-787
12. Gurbel P.A., Bliden K.P., and Tantry U.S. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol 48 (2006) 2186-2191
13. Gurbel P.A., Bliden K.P., Zaman K.A., Yoho J.A., Hayes K.M., and Tantry U.S. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111 (2005) 1153-1159
14. Frere C., Cuisset T., Morange P.E., Quilici J., Camoin-Jau L., Saut N., Faille D., Lambert M., Juhan-Vague I., Bonnet J.L., and Alessi M.C. Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 101 (2008) 1088-1093
15. Fontana P., Senouf D., and Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res 121 (2008) 463-468
16. Giusti B., Gori A.M., Marcucci R., Saracini C., Sestini I., Paniccia R., Valente S., Antoniucci D., Abbate R., and Gensini G.F. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 17 (2007) 1057-1064
17. Suh J.W., Koo B.K., Zhang S.Y., Park K.W., Cho J.Y., Jang I.J., Lee D.S., Sohn D.W., Lee M.M., and Kim H.S. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 174 (2006) 1715-1722
18. Lau W.C., and Gurbel P.A. Antiplatelet drug resistance and drug-drug interactions: role of cytochrome P450 3A4. Pharmacol Rev 23 (2006) 2691-2708
19. Hulot J.S., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., Aiach M., Lechat P., and Gaussem P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108 (2006) 2244-2247
20. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramírez C., Cavallari U., Trabetti E., Sabaté M., Hernández R., Moreno R., Escaned J., Alfonso F., Bañuelos C., Costa M.A., Bass T.A., Pignatti P.F., and Macaya C. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 26 (2006) 1895-1900
21. Lau W.C., Waskell L.A., Watkins P.B., Neer C.J., Horowitz K., Hopp A.S., Tait A.R., Carville D.G., Guyer K.E., and Bates E.R. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107 (2003) 32-37
22. Malinin A., Pokov A., Swaim L., Kotob M., and Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 28 (2006) 315-322
23. Jakubowski J.A., Payne C.D., Li Y.G., Brandt J.T., Small D.S., Farid N.A., Salazar D.E., and Winters K.J. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 99 (2008) 409-415
24. Malinin A., Pokov A., Spergling M., Defranco A., Schwartz K., Schwartz D., Mahmud E., Atar D., and Serebruany V. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 119 (2007) 277-284
25. Lee S.W., Park S.W., Kim Y.H., Yun S.C., Park D.W., Lee C.W., Hong M.K., Kim H.S., Ko J.K., Park J.H., Lee J.H., Choi S.W., Seong I.W., Cho Y.H., Lee N.H., Kim J.H., Chun K.J., and Park S.J. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 51 (2008) 1181-1187
26. Savi P., Combalbert J., Gaich C., Rouchon M.C., Maffrand J.P., Berger Y., and Herbert J.M. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 72 (1994) 313-317
27. De Morais S.M., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., and Goldstein J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46 (1994) 594-598
28. Xie H.G., Kim R.B., Wood A.J., and Stein C.M. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41 (2001) 815-850
29. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A., and Costa M.A. Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516